Abstract
Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.
Keywords: HMG-CoA reductase inhibitor, pneumonia
Current Respiratory Medicine Reviews
Title: The Potential Role of Statins in Pneumonia
Volume: 6 Issue: 3
Author(s): Brandy Nakashima, Marcos I. Restrepo, Antonio Anzueto and Eric M. Mortensen
Affiliation:
Keywords: HMG-CoA reductase inhibitor, pneumonia
Abstract: Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.
Export Options
About this article
Cite this article as:
Nakashima Brandy, I. Restrepo Marcos, Anzueto Antonio and M. Mortensen Eric, The Potential Role of Statins in Pneumonia, Current Respiratory Medicine Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339810791526193
DOI https://dx.doi.org/10.2174/157339810791526193 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Regulation of Myocardial Homeostasis, Self-Regeneration and Senescence
Current Drug Targets The Utility of Emerging Biomarkers and Imaging for Assessment of Cardiovascular Risk
Current Vascular Pharmacology Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry ATP Binding Cassette Transporter A1 (ABCA1) Associated Proteins:Potential Drug Targets in the Metabolic Syndrome and Atherosclerotic Disease?
Current Pharmaceutical Biotechnology Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Novel Antiinflammatory and Antiinfective Agents
Anti-Infective Agents in Medicinal Chemistry Dietary Potassium in Cardiovascular Prevention: Nutritional and Clinical Implications
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents ABC Transporters and Sterol Absorption
Current Drug Targets - Cardiovascular & Hematological Disorders Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Cellular Protection and Therapeutic Potential of Tocotrienols
Current Pharmaceutical Design The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde
Current Cancer Drug Targets Antibiotics with Antiviral and Anti-Inflammatory Potential Against Covid-19: A Review
Current Reviews in Clinical and Experimental Pharmacology Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?
Current Medicinal Chemistry